Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
MISC (50)
- 五十嵐 勉, 高橋 和久, 三宅 弘一, 小林 舞香, 矢口 智恵美, 山崎 吉之, 三宅 紀子, 亀谷 修平, 島田 隆, 岡田 尚巳, et al. AAVベクターの硝子体投与における内境界膜剥離併用硝子体手術とサル網膜への遺伝子導入改善効果と安全性の検討. 眼科臨床紀要. 2018. 11. 7. 554-554
- 五十嵐 勉, 高橋 和久, 三宅 弘一, 小林 舞香, 矢口 智恵美, 山崎 吉之, 三宅 紀子, 亀谷 修平, 島田 隆, 岡田 尚巳, et al. アデノ随伴ウイルスベクターによる遺伝子治療と内境界膜剥離. 日本眼科学会雑誌. 2018. 122. 3. 251-252
- 五十嵐 勉, 高橋 和久, 三宅 弘一, 小林 舞香, 矢口 智恵美, 山崎 吉之, 喜納 裕美, 三宅 紀子, 亀谷 修平, 島田 隆, et al. サルに対するAAVベクター硝子体投与による血中抗体価の検討. 日本眼科学会雑誌. 2018. 122. 臨増. 260-260
- Kazuhisa Takahashi, Tsutomu Igarashi, Koichi Miyake, Maika Kobayashi, Chiemi Yaguchi, Osamu Iijima, Yoshiyuki Yamazaki, Noriko Miyake, Shuhei Kameya, Takashi Shimada, et al. Efficient Transduction of Inner Retina by Surgical Internal Limiting Membrane (ILM) Peeling Before Intravitreal AAV Vector Injection in Cynomolgus Monkeys. MOLECULAR THERAPY. 2017. 25. 5. 111-111
- Noriko Miyake, Koichi Miyake, Motoko Yamamoto, Takashi Shimada, Takashi Okada. Why Are scAAV9 Vectors Able to Pass Through the BBB but Not ssAAV9?; The Difference Between the ssAAV9 and scAAV9 Vector in Transduction of CNS by Intravenous Injection. MOLECULAR THERAPY. 2017. 25. 5. 320-321
- M. Kobayashi, T. Igarashi, K. Miyake, N. Miyake, K. Nakamoto, Y. Hirai, H. Takahashi, T. Okada. Tyrosine-mutated AAV2 (Y730, 500, 444F) mediated BDNF rescued inner retina in rat retinal ischemic injury model. HUMAN GENE THERAPY. 2016. 27. 11. A122-A123
- 坂井敦, 丸山基世, 丸山基世, 三宅紀子, 齋藤文仁, 三宅弘一, 島田隆, 岡田尚巳, 鈴木秀典. 神経障害性疼痛におけるmiR-17-92クラスターによるカリウムチャネルの調節. Pain Research. 2016. 31. 2. 86
- Noriko Miyake, Koichi Miyake, Motoko Yamamoto, Takashi Shimada, Takashi Okada. Successful Treatment of Neonatal Metachromatic Leukodystrophy Model Mice by Low Dose of Self-Complementary AAV Type9 Vector Expressing ASA. MOLECULAR THERAPY. 2016. 24. S63-S63
- 五十嵐 勉, 三宅 弘一, 小林 舞香, 高橋 和久, 三宅 紀子, 中元 兼二, 岡田 尚巳, 高橋 浩. BDNFを発現するチロシン変異AAV2を用いた網膜虚血モデルにおける神経保護効果. 眼科臨床紀要. 2015. 8. 10. 772-772
- 五十嵐 勉, 三宅 弘一, 中元 兼二, 小林 舞香, 亀谷 修平, 三宅 紀子, 飯島 脩, 岡田 尚巳, 島田 隆, 高橋 浩. 網膜一過性虚血モデルにおけるチロシン変異AAV2ベクター由来BDNFの神経保護効果. 日本緑内障学会抄録集. 2015. 26回. 114-114
- I. Omori, H. Yamaguchi, T. Kitano, N. Miyake, K. Miyake, D. Kazuo, K. Inokuchi. THE D816V C-KIT MUTATION HAS HIGHER ABILITY OF JAK-STAT AND SRC FAMILY KINASE THAN N822K C-KIT MUTATION, AND THEREFORE PROLIFERATION ACTIVITY IS HIGH IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA. 2015. 100. 353-354
- Aki Nakamura, Koichi Miyake, Atsushi Watanabe, Yukihiko Hirai, Noriko Miyake, Osamu Iijima, Kumi Adachi, Hideaki Kinoshita, Taku Noguchi, Shinichi Abe, et al. Prolonged Survival and Improved Phenotypes of Lethal Hypophosphatasia Model Mice By Adeno-Associated Virus-Mediated Muscle Transduction of Bone-Targeted Alkaline Phosphatase. MOLECULAR THERAPY. 2015. 23. S282-S282
- Ikuko Omori, Hiroki Yamaguchi, Tomoaki Kitano, Noriko Miyake, Koichi Miyake, Koiti Inokuchi. The D816V C-Kit Mutation Confers Higher Proliferation Activity By JAK-STAT and Src Family Kinase Pathways Compared to N822K C-Kit Mutation in Core-Binding Factor Acute Myeloid Leukemia. BLOOD. 2014. 124. 21
- Noriko Miyake, Koichi Miyake, Atsushi Sakai, Motoko Yamamoto, Ayumi Endo, Hidenori Suzuki, Takashi Shimada. Gene Therapy for MLD by Intrathecal Administration of Type 9 AAV Vector Expressing ASA. JOURNAL OF GENE MEDICINE. 2014. 16. 7-8. 252-253
- Koichi Miyake, Tae Matsumoto, Noriko Miyake, Hideo Orimo, Yoshitaka Fukunaga, Takashi Shimada. AAV Type 8 Mediated Bone-Targeted and Muscle Directed Neonatal Gene Therapy for Hypophosphatasia. JOURNAL OF GENE MEDICINE. 2014. 16. 7-8. 274-275
- Nagisa Asakawa, Tsutomu Igarashi, Noriko Miyake, Koichi Miyake, Takashi Shimada, Hiroshi Takahashi. Direct Comparison of Administration Routes for AAV 8 Mediated Ocular Gene Therapy. JOURNAL OF GENE MEDICINE. 2014. 16. 7-8. 254-255
- Tsutomu Igarashi, Koichi Miyake, Maika Kobayashi, Kazuhisa Takahashi, Noriko Miyake, Osamu Iijima, Kenji Nakamoto, Yukihiko Hirai, Takashi Shimada, Hiroshi Takahashi. Efficient Protection of Retina By Tyrosine-Mutated Self-Complementary AAV2 Vector Encoding BDNF in a Rat Retinal Ischemic Injury Model. MOLECULAR THERAPY. 2014. 22. S47-S47
- Noriko Miyake, Koichi Miyake, Motoko Yamamoto, Takashi Shimada. Successful Treatment of Adult MLD Model Mice By Intravenous Injection of Self-Complementary Type 9 AAV Vector Expressing ASA. MOLECULAR THERAPY. 2014. 22. S151-S151
- Noriko Miyake, Koichi Miyake, Takashi Shimada. Gene therapy of MLD model mice by intrathecal and intravenous injection of AAV9 vector. MOLECULAR GENETICS AND METABOLISM. 2014. 111. 2. S78-S79
- 坂井敦, 三宅紀子, 三宅弘一, 島田隆, 鈴木秀典. 一次感覚神経において神経障害性疼痛特異的に発現変化するマイクロRNAの解析. Pain Research. 2014. 29. 2
Return to Previous Page
